{"schema_version":"secwatch.filing_event.v1","accession":"0001804220-23-000021","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.831180+00:00","generated_at":"2026-06-12T10:31:20.461142+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Regeneron Q2 revenues up 11% to $3.16B; EPS $8.50 GAAP/$10.24 non-GAAP","bullets":["Q2 2023 total revenues $3.158B (+11% YoY); GAAP diluted EPS $8.50 (up 14%); non-GAAP diluted EPS $10.24 (up 5%).","Dupixent global net sales (Sanofi) rose 33% to $2.79B; EYLEA US net sales fell 7% to $1.50B on lower pricing/competition.","FDA issued CRL for aflibercept 8 mg due to contract manufacturer issues; expects FDA action on BLA in Q3 2023.","Repurchased $723M in shares during Q2; $2.3B remained under buyback program as of June 30, 2023.","Updated 2023 guidance: GAAP R&D $4.315-4.455B; non-GAAP R&D $3.825-3.925B; SG&A and gross margin ranges unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001804220-23-000021","json":"https://secwatch.observer/filing/0001804220-23-000021.json","markdown":"https://secwatch.observer/filing/0001804220-23-000021.md","text":"https://secwatch.observer/filing/0001804220-23-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000180422023000021/0001804220-23-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000180422023000021/regn-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T10:31:20.461142+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9971e050921a751e9b6a799093236062dda81cb6","claim":"REGENERON PHARMACEUTICALS, INC. reported the quarter ended June 30, 2023 results: revenue $3.16 billion, EPS $8.50.","evidence_excerpt":"EXHIBIT 99.1 Document Exhibit 99.1 Press Release Regeneron Reports Second Quarter 2023 Financial and Operating Results • Second quarter 2023 revenues increased 11% to $3.16 billion versus second quarter 2022 • Second quarter 2023 Dupixent ® global net sales (recorded by Sanofi) increased 33% to $2.79 billion versus second quarter 2022 • Second quarter 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000180422023000021/0001804220-23-000021-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$3.16 billion"},{"label":"EPS","value":"$8.50"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}